IDH1 and diffuse astrocytoma: Therefore, our remit was to assess the influence of treatment regimens by analyzing the clinical course of a large cohort of IDH1/2 wt diffuse astrocytoma patients from six neurosurgical sites treated in the 2016–2019 period.